Related Experiment Video
Updated: Jul 18, 2025
Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition
Published on: August 18, 2022
CD30 in Cutaneous Pathology
Angel Fernandez-Flores1,2,3, David Cassarino4
1Dermatopathologist, Department of Histopathology, University Hospital El Bierzo, Ponferrada, Spain.
Abstract:
The discovery of CD30 as a diagnostic marker was essential in the identification of not only some lymphomas but also many other solid tumors and benign reactive conditions. Many CD30+ cutaneous disorders and tumors have been categorized since the identification of the marker. With the design of targeted therapies against CD30+ tumoral cells, the interest in CD30 determination was not only diagnostic but also mainly therapeutic. In this article, we explore the historical aspects of the discovery of CD30 and examine the main CD30-related cutaneous pathology, susceptible of anti-CD30 modern treatments.
Insights
The discovery of CD30 as a diagnostic marker aids in identifying lymphomas, solid tumors, and benign conditions. Its therapeutic potential is growing with targeted anti-CD30 treatments for CD30+ cancers.
Area of Science:
- Immunology
- Dermatology
- Oncology
Background:
- CD30 is a crucial diagnostic marker identified in various lymphomas, solid tumors, and benign conditions.
- The significance of CD30 extends beyond diagnosis, particularly in therapeutic applications for CD30-expressing malignancies.
- Numerous CD30-positive cutaneous disorders and tumors have been classified since the marker's discovery.
Purpose of the Study:
- To explore the historical context of CD30 discovery.
- To review CD30-related cutaneous pathology.
- To discuss the therapeutic implications of targeting CD30 in modern treatments.
Main Methods:
- Literature review of historical data on CD30.
- Analysis of studies categorizing CD30+ cutaneous disorders.
- Examination of research on targeted anti-CD30 therapies.
Main Results:
- CD30's role as a diagnostic marker for diverse conditions is well-established.
- A growing number of CD30+ skin conditions are recognized.
- Targeted therapies against CD30+ cells show therapeutic promise.
Conclusions:
- CD30 is vital for diagnosing and understanding various neoplasms and reactive conditions.
- Cutaneous CD30+ pathologies are increasingly recognized and relevant for targeted therapy.
- The therapeutic targeting of CD30 represents a significant advancement in treating CD30-driven diseases.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
